EPIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EPIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Operating Margin % is calculated as Operating Income divided by its Revenue. ESSA Pharma's Operating Income for the three months ended in Dec. 2023 was $-7.60 Mil. ESSA Pharma's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, ESSA Pharma's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.
The historical rank and industry rank for ESSA Pharma's Operating Margin % or its related term are showing as below:
ESSA Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
ESSA Pharma's Operating Income for the three months ended in Dec. 2023 was $-7.60 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-31.87 Mil.
The historical data trend for ESSA Pharma's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESSA Pharma Annual Data | |||||||||||||||||||||
Trend | Sep14 | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
Operating Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
ESSA Pharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Operating Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, ESSA Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ESSA Pharma's Operating Margin % distribution charts can be found below:
* The bar in red indicates where ESSA Pharma's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
ESSA Pharma's Operating Margin % for the fiscal year that ended in Sep. 2023 is calculated as
Operating Margin % | = | Operating Income (A: Sep. 2023 ) | / | Revenue (A: Sep. 2023 ) |
= | -32.134 | / | 0 | |
= | % |
ESSA Pharma's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as
Operating Margin % | = | Operating Income (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | -7.595 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESSA Pharma (NAS:EPIX) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of ESSA Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Virsik | officer: Chief Operating Officer | 131 ESCANYO WAY, PORTOLA VALLEY CA 94028 |
David Ross Parkinson | director, officer: Chief Executive Officer | C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Franklin M Berger | director | 1000 MARINA BLVD, STE 200, BRISBANE CA 94005 |
Lauren Merendino | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
David S. Wood | officer: Chief Financial Officer | 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4 |
Biotech Growth N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Philip W. Kantoff | director | 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf I Gp Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Partners Os Ltd. | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Mark N Lampert | 10 percent owner | 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
Biotechnology Value Fund Ii Lp | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Inc/il | 10 percent owner | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Partners L P/il | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By PRNewswire PRNewswire • 02-07-2023
By PRNewswire • 10-24-2023
By PRNewswire • 12-27-2023
By PRNewswire PRNewswire • 07-12-2022
By PRNewswire • 09-18-2023
By GuruFocus Research • 12-12-2023
By PRNewswire • 10-21-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire PRNewswire • 02-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.